Efficacy of ozonized sunflower oil as treatment of canine generalized demodicosis
Published on: 18th March, 2021
OCLC Number/Unique Identifier: 9124663088
Background: The acaricidal action of Ozonized sunflower oil (OSO) has demonstrated in different clinical cases of different animal species, such as psoroptic rabbits and pig sarcoptic scabies and recently in demodesic goat.
Objectives: This study evaluated the effectiveness of OSO as treatment for generalized demodicosis mange in dogs.
Animals: Twenty dogs of different breeds, between six months and one year of age with generalized demodicosic mange that attended to Veterinary Clinic “José Luis Callejas” Havana, Cuba, during the year 2015, were included in the study.
Methods: The demodicosis diagnostic was based on its clinical history, the mite’s presence by deep scraping and clinical signs. All cases had a history of receiving before conventional treatments without solution. OSO treatment was topically applied daily, every 12 hours, after shaving all affected areas. Monitoring of clinical signs, mite counting on scaling, pruritus and capillary regrowth (7, 14, 28, 56 and 84 days) were performed.
Results: The results showed a significant reduction of mite counts, clinical signs and pruritus since the 7th day of application. The animals recovered the fur on more than 90% of the body surface. All the animals (100%) recovered from generalized demodesic mange in 84 days of treatment.
Conclusion: The effectiveness and safety of OSO as election treatment of generalized demodicosis mange in dogs was demonstrated.
Blog Section
Search by University/Institution
Enter your University/Institution to find colleagues at HSPI.
Ensuring author's satisfaction with
- Friendly and hassle-free publication process
- Less production time of articles
- Constructive peer-review
- Enhancing journal reputation
- Regular feedback system
- Quick response to authors' queries
Most Viewed Keywords
- Child obesity
- Biological post
- Morbidity
- COVID-19
- Cholera
- Beta-thalassemia
- Packed cell volume
- Albino mice
- Major risk factors
- Gene therapy, Duchenne muscular dystrophy, CRISPR/Cas9, Animal model
- Knowledge
- Tinnitus
- Police
- Myxedema
- Embryonal rhabdomyosarcoma
- Oral appliance
- Spinal Muscular Atrophy (SMA)
- Zymosan-induced arthritis
- COVID-19
- Liver metastases
Search Articles by Country
Get all latest articles in all Heighten Science Publications Inc journals by country.
Testimonials
I am very much pleased with the fast track publication by your reputed journal's editorial team. It is really helpful for researchers like me from developing nations. I strongly recommend your journ...
Badri Kumar Gupta
Congratulations for the excellence of your journal and high quality of its publications.
Angel MARTIN CASTELLANOS
Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.
Ayokunle Dada
Your service is excellent. Processing and editing were very fast. I hope to publish more of my works in your journal.
Ausraful Islam
Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as...
Elizabeth Awoyesuku
I very much appreciate the humanitarian services provided in my stead by this journal/publisher. It exhibits total absence of editorial impertinence. As an Author, I have been guided to have a fruitf...
Chrysanthus Chukwuma
It was a great experience publishing through JCICM. The article has reached out to several institutions. Appreciate your professional work. Hope to work with you again
Anas Wardeh
Really good service with prompt response. Looking forward to having long lasting relationship with your journal
Avishek Bagchi
Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.
Ekiti State University Teaching Hospital, Nigeria
Ayokunle Dada
I hope to ability to make some new investigation and publish in Your Company in future.